Gregory D. Davis - 18 Oct 2024 Form 3 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: Head of Research & Technology
Issuer symbol: SGMO
Report date: 18 Oct 2024
Net transaction value: $0
Form type: 3
Accepted by SEC: 28 Oct 2024, 16:11:50 UTC
Next filing: 26 Nov 2024
SEC filing: View on sec.gov
Reporting owner signature: /s/ Ron A. Metzger, Attorney-in-Fact

Key filing fact

Gregory D. Davis filed Form 3 for SANGAMO THERAPEUTICS, INC (SGMO) on 28 Oct 2024.

Key facts

This page summarizes Gregory D. Davis's Form 3 filing for SANGAMO THERAPEUTICS, INC (SGMO).
0 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 28 Oct 2024, 16:11.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC Source

Ownership activity is grounded in SEC Form 3 disclosures.

See Original Filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGMO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 203,089
Date: 18 Oct 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGMO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $9.16
Footnotes: F2

SGMO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $11.19
Footnotes: F3

SGMO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,225
Exercise price: $5.90
Footnotes: F4

SGMO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,688
Exercise price: $2.66
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

1. Includes (a) 2,836 shares subject to the Reporting Person's February 25, 2022 restricted stock unit ("RSU") grant that will vest in successive equal quarterly installments through February 25, 2025, (b) 12,129 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 150,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.

Footnote F2

Fully vested and exercisable.

Footnote F3

One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2021 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Footnote F4

One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2022 grant date, and the remainder of the shares subject to the option vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Footnote F5

One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 24, 2023 grant date, and the remainder of the shares subject to the option will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .